anticoagulant - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID-19 mild to moderate
anticoagulant
anticoagulant, curative dose	ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose	RAPID ...

23 studies excluded by filtering options 0

5071	Tang, 2020	1	13	3		not a RCT	high risk of bias
5355	Paranjpe, 2020	1	13	4		not a RCT	high risk of bias
5404	Tremblay, 2020	1	13	0		not a RCT	risk of bias not avaialble
5441	Ayerbe, 2020	1	13	0		not a RCT	risk of bias not avaialble
5679	ATTACC (Houston), 0	0	1	0	selection pending
5777	Bousquet, 2020	1	13	0		not a RCT	risk of bias not avaialble
5777	Bousquet, 2020	1	13	0		not a RCT	risk of bias not avaialble
5845	ACTIV-4a (heparin), 0	0	1	0	selection pending
5889	REMAP-CAP Anticoagulation, 0	0	1	0	selection pending
5891	HEP-COVID, 2021	0	1	0	selection pending
5895	X-COVID-19, 2021	0	1	0	selection pending
6283	Lynn, 2020	0	13	0	selection pending
6364	Denas, 2020	0	0	0	selection pending
6393	Rossi, 2020	1	13	0		not a RCT	risk of bias not avaialble
6396	Russo, 2020	1	13	0		not a RCT	risk of bias not avaialble
6404	Trinh, 2020	1	13	0		not a RCT	risk of bias not avaialble
6405	Li [retracted], 2020	2	0	0	excluded		risk of bias not avaialble
6406	Gonzalez-Porras, 2020	1	13	0		not a RCT	risk of bias not avaialble
6406	Gonzalez-Porras, 2020	1	13	0		not a RCT	risk of bias not avaialble
6439	Gonzalez-Ochoa, 2020	0	0	0	selection pending
6448	Ménager, 2020	0	0	0	selection pending
9169	MICHELLE, 2021	0	1	0	selection pending
10523	FREEDOM COVID, 2023	0	1	0	selection pending